EUROAPI has announced a strategic partnership with Spirochem, a Swedish contract research organisation. This collaboration is set to enhance EuroAPI’s contract development and manufacturing organisation (CDMO) capabilities, offering its customers a consolidated CRO-CDMO solution. The partnership comes at a time when the
Alcami Corporation, the US-based contract development and manufacturing organization (CDMO), announced that it has completed the acquisition of Pacific Pharmaceutical Services, Inc. (PPS), a preferred provider of cGMP pharma storage and services. This acquisition is Reno, Nevada, a strategic location
Olon Group, a leading API supplier and contract manufacturer, has announced the construction of a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite in Concord, Ohio. This suite is set to significantly expand Olon’s capabilities to serve clients developing innovative
AbbVie has announced a significant investment of $223 million in a new biologics manufacturing facility in Singapore. The expansion will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. The construction will commence immediately with
Suanfarma, a leader in the B2B life science business, has announced a strategic rebranding initiative aimed at reinforcing its position as both as a distributor of APIs and as a CDMO company in the production of active pharmaceutical ingredients. The
Our expert panel share best practices for how to negotiate for yourself effectively, overcome common barriers, and close the gender pay gap.
Scott Schliebner shares his insights on clinical research, and how to navigate the CRO industry
Kindeva Drug Delivery has announced the acquisition of Summit Biosciences Inc., an intranasal drug-delivery CDMO. This strategic move not only adds a new drug-delivery platform to Kindeva’s portfolio but also expands its capabilities across a wider range of complex drug-device combination
Malik Akhtar explains the “Three C” procurement strategy which defines the areas of greatest focus for Bayer in 2024.
CEO Olivier Rousseau sets out his plans for 2024 and explains how the whole company is now lazer-focused on being the most sustainable in the industry.
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
